These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10631459)

  • 1. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.
    Thirion P; Wolmark N; Haddad E; Buyse M; Piedbois P
    Ann Oncol; 1999 Nov; 10(11):1317-20. PubMed ID: 10631459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
    Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
    Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
    Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
    ; Piedbois P; Buyse M; Kemeny N; Rougier P; Carlson R; Allen-Mersh T; O'Connell M; Chang A; Sondak V; Kemeny M; Levy E
    J Natl Cancer Inst; 1996 Mar; 88(5):252-8. PubMed ID: 8614003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma.
    Lorenz M; Müller HH
    J Clin Oncol; 2000 Jan; 18(2):243-54. PubMed ID: 10637236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
    Benson AB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.
    O'Connell MJ; Nagorney DM; Bernath AM; Schroeder G; Fitzgibbons RJ; Mailliard JA; Burch P; Bolton JS; Colon-Otero G; Krook JE
    J Clin Oncol; 1998 Jul; 16(7):2528-33. PubMed ID: 9667274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.
    Kemeny N; Conti JA; Sigurdson E; Cohen A; Seiter K; Lincer R; Niedzwiecki D; Botet J; Chapman D; Costa P
    Cancer; 1993 Mar; 71(6):1964-71. PubMed ID: 8443746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
    Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
    J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
    Kemeny N; Huang Y; Cohen AM; Shi W; Conti JA; Brennan MF; Bertino JR; Turnbull AD; Sullivan D; Stockman J; Blumgart LH; Fong Y
    N Engl J Med; 1999 Dec; 341(27):2039-48. PubMed ID: 10615075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
    Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
    BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
    Goldberg RM
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):21-8. PubMed ID: 9786313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
    Stagg RJ; Venook AP; Chase JL; Lewis BJ; Warren RS; Roh M; Mulvihill SJ; Grobman BJ; Rayner AA; Hohn DC
    J Natl Cancer Inst; 1991 Mar; 83(6):423-8. PubMed ID: 1825674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
    Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
    Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
    Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
    Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
    Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases].
    Gassel HJ; Müller HH; Mattes P; Stieger R; Schramm H; Lorenz M
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1458-60. PubMed ID: 9931911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
    Link KH; Sunelaitis E; Kornmann M; Schatz M; Gansauge F; Leder G; Formentini A; Staib L; Pillasch J; Beger HG
    Cancer; 2001 Dec; 92(11):2746-53. PubMed ID: 11753947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
    Comella P; Crucitta E; De Vita F; De Lucia L; Farris A; Del Gaizo F; Palmeri S; Lannelli A; Mancarella S; Tafuto S; Maiorino L; Buzzi F; De Cataldis G;
    Ann Oncol; 2002 Jun; 13(6):866-73. PubMed ID: 12123331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.